Babesiosis medical therapy
|
Babesiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Babesiosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Babesiosis medical therapy |
|
Risk calculators and risk factors for Babesiosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ilan Dock, B.S.
Overview
The mainstay of therapy for babesiosis is antimicrobial therapy. Patients with mild or moderate disease are treated with a combination of Atovaquone and Azithromycin. Patients with severe disease are treated with either Clindamycin or Clindamycin and Quinine. In life-threatening cases, exchange transfusion is performed.
Medical Therapy
The traditional regimen of Quinine and Clindamycin is often poorly tolerated; recent evidence suggests that a regimen of Atovaquone and Azithromycin can be equally effective [1]. In life-threatening cases, exchange transfusion is performed. In this procedure, the infected red blood cells are removed and replaced with fresh ones.
Antimicrobial Regimen
- Treatment
- 1. Mild/moderate disease[2]
- Preferred regimen: Atovaquone 750 mg PO bid AND Azithromycin 600 mg PO qd for 7-10 days
- 2. Severe disease:
- Preferred regimen: Clindamycin 600 mg PO tid AND Quinine 650 mg PO tid for 7–10 days
- Preferred regimen: Clindamycin 1.2 g IV q12h
- Note (1): For overwhelming infection in asplenic patients and immunocompromised patients, treat for 6 or more weeks.
- Note (2): Consider transfusion if 10% parasitemia.
References
- ↑ Krause P, Lepore T, Sikand V, Gadbaw J, Burke G, Telford S, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A (2000). "Atovaquone and azithromycin for the treatment of babesiosis". N Engl J Med. 343 (20): 1454–8. PMID 11078770.
- ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.